Exploring MFN Policy Effectiveness in Drug Pric...

By João L. Carapinha

February 19, 2026

MFN Policy Effectiveness in Countering Freeloading Claims The MFN policy effectiveness is evident in the coalition letter dated February 12, 2026, which opposes codifying Mos...
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision
Launch of TrumpRx Drug Pricing: Savings on Essential Medications
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
NHS Cost-Effectiveness Thresholds Boost Drug Approvals and Innovation
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Biomanufacturing Excellence Act: Strengthening U.S. Biopharmaceutical Manufac...
Medicare Drug Price Negotiations: Major Savings for Seniors on Cancer and Chr...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...